A meta-analysis of an scRNAseq dataset from melanoma patients treated with checkpoint inhibitors (anti-PD-1, anti-CTLA4 + anti-PD-1 or anti-CTLA4) revealed that TREM2high TAMs were 15.1-fold more abundant in non-responders [70]. The gene discussed is CTLA4; the disease is melanoma.